Your browser doesn't support javascript.
loading
Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.
Damiano, Jason S; Rendahl, Katherine G; Karim, Christopher; Embry, Millicent G; Ghoddusi, Majid; Holash, Jocelyn; Fanidi, Abdallah; Abrams, Tinya J; Abraham, Judith A.
Affiliation
  • Damiano JS; Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA. Jason.damiano@novartis.com
Mol Cancer Ther ; 12(3): 295-305, 2013 Mar.
Article in En | MEDLINE | ID: mdl-23270929
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Prolactin / Breast Neoplasms / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal / Neoplasms, Hormone-Dependent Limits: Animals / Female / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2013 Document type: Article Affiliation country: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Prolactin / Breast Neoplasms / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal / Neoplasms, Hormone-Dependent Limits: Animals / Female / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2013 Document type: Article Affiliation country: Estados Unidos